ecancermedicalscience最新文献

筛选
英文 中文
Lympho-epithelial carcinoma of the larynx - the big masquerader of squamous cell carcinoma - a case report. 喉部淋巴上皮癌-鳞状细胞癌的大伪装者1例报告。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-27 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1936
Samapika Bhaumik, Prarabdh Singh, Narapareddy Venkata Dinesh Reddy, Shreya Jain, Sambit S Nanda, Paramita Paul, Ashutosh Mukherji, Satyajit Pradhan
{"title":"Lympho-epithelial carcinoma of the larynx - the big masquerader of squamous cell carcinoma - a case report.","authors":"Samapika Bhaumik, Prarabdh Singh, Narapareddy Venkata Dinesh Reddy, Shreya Jain, Sambit S Nanda, Paramita Paul, Ashutosh Mukherji, Satyajit Pradhan","doi":"10.3332/ecancer.2025.1936","DOIUrl":"10.3332/ecancer.2025.1936","url":null,"abstract":"<p><strong>Background: </strong>Lympho-epithelial carcinoma (LEC) is most commonly found in the nasopharynx, while LEC of the hypopharynx and larynx is rare, with fewer than 50 cases in the published literature. As the non-nasopharyngeal presentations are rare, the clinical course, diagnosis and treatment for this tumour are sparsely reported. Here, we report a rare case report of Epstein-Barr virus negative laryngeal LEC treated with combined modality therapy in a tertiary care centre. We also review the literature regarding currently acceptable treatment strategies.</p><p><strong>Case presentation: </strong>We present a case of a 59-year-old male who presented with hoarseness of voice and acute onset of respiratory distress. Post emergency tracheostomy for respiratory distress, evaluation with contrast-enhanced computed tomography head and neck revealed cT3N0M0 supraglottic disease. Biopsy revealed poorly differentiated carcinoma. In view of thyroid cartilage erosion, the patient underwent two cycles of neo-adjuvant chemotherapy followed by total laryngectomy, bilateral neck dissection and primary closure. Postoperative histopathology revealed ypT1N0 LEC, with adequate margins and adequate neck dissection. The patient was then treated with adjuvant chemoradiotherapy. 6 months follow-up positron emission tomography/computed comography shows no locoregional disease.</p><p><strong>Conclusion: </strong>The treatment for rare cases like non-nasopharyngeal LEC is yet to be standardised. However, as seen in our case report, multimodality management including surgery, chemotherapy and radiation therapy seems to be a feasible approach to managing such rare cases of non-nasopharyngeal LEC.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1936"},"PeriodicalIF":1.2,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer health literacy profile in Argentine oncology patients. 阿根廷肿瘤患者的癌症健康素养概况。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-27 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1934
Karen M Manzur, Ana Kohan Cortada
{"title":"Cancer health literacy profile in Argentine oncology patients.","authors":"Karen M Manzur, Ana Kohan Cortada","doi":"10.3332/ecancer.2025.1934","DOIUrl":"10.3332/ecancer.2025.1934","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer Health Literacy is the individual's ability to seek, understand, evaluate and use basic information and services necessary to make appropriate decisions regarding cancer prevention, diagnosis and treatment. The aim of this study was to analyse the Health Literacy Profile of Argentine cancer patients.</p><p><strong>Methodology: </strong>A non-experimental, descriptive, cross-sectional design was used. A non-probabilistic sampling method was applied and 500 adult cancer patients who provided their consent participated. A sociodemographic questionnaire and the Cancer Health Literacy Test were administered. Data were collected through mixed methods and analysed using R Studio.</p><p><strong>Results: </strong>The average Cancer Health Literacy score was 22.01 points (SD = 5.68, Mdn = 24), with 73% of patients classified at an intermediate level. Multiple linear regression analysis revealed that educational level and information-seeking behaviour regarding diet and cancer were significant contributing factors to this construct, explaining 30.6% of its variability (adjusted <i>R</i> <sup>2</sup> = 0.306) with a large effect size (f<sup>2</sup> = 0.44). Cancer Health Literacy was lower in patients with an incomplete secondary education or lower and higher in those who actively sought information.</p><p><strong>Conclusion: </strong>Cancer Health Literacy was associated with educational level and nutritional information-seeking behaviour. Measuring these factors in clinical practice contributes to evidence-based care.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1934"},"PeriodicalIF":1.2,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An overview of the presentation and management of vulvovaginal cancers at the NSIA-LUTH Cancer Centre. 概述外阴阴道癌的表现和管理在NSIA-LUTH癌症中心。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-27 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1935
Chidiebere I Agbakwuru, Eben Aje, Mutiu Jimoh, Anthonia Sowunmi, Samson Ezekiel
{"title":"An overview of the presentation and management of vulvovaginal cancers at the NSIA-LUTH Cancer Centre.","authors":"Chidiebere I Agbakwuru, Eben Aje, Mutiu Jimoh, Anthonia Sowunmi, Samson Ezekiel","doi":"10.3332/ecancer.2025.1935","DOIUrl":"10.3332/ecancer.2025.1935","url":null,"abstract":"<p><strong>Background: </strong>Vulvovaginal cancer (VVC) are two rare malignancies in women which are less prevalent than other gynecological cancer.</p><p><strong>Aim: </strong>This study seeks to investigate the evaluation of the presentation and management of VVC cases at our institution, aiming to contribute to a deeper understanding of VVC within sub-Saharan Africa.</p><p><strong>Methods: </strong>This was a retrospective study of all VVC cases seen at the NSIA-LUTH Cancer Centre from May 2019 to June 2024. Data on clinical presentation and treatment modalities were collated and analysed using the Statistical Package for Social Science version 27.0.</p><p><strong>Results: </strong>Out of a total of 10,376 cancer cases reported during the study period, 0.6% (67 cases) were accounted as VVC, the median age at presentation was 54 years range: 32-88 years). Vaginal bleeding (41.8%), lump (41.8%) and vaginal swelling (32.8%) were the major presenting symptoms. Immunosuppression Human Immunodeficiency Virus, alcohol, multiple sexual partners and family history of cancer were the most identified risk factors. Histological examination identified squamous cell carcinoma as the predominant subtype (74.8%). Most cases were diagnosed at stage IV (52.2%). Treatment uptake was average, with 23.9% received surgery, 40.3% receiving chemotherapy and 56.7% undergoing radiotherapy.</p><p><strong>Conclusion: </strong>The incidence of VVC is increasing in Nigeria, particularly among young women. This study showed late presentation and advanced-stage cancer with vaginal bleeding, lump and vaginal swelling as the most presenting symptoms. It is imperative to increase awareness, which potentially facilitates early detection of the disease.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1935"},"PeriodicalIF":1.2,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary treated versus referred trunk and extremities soft tissue sarcomas: comparative analysis of initial treatment impact on disease control. 初步治疗与转诊躯干和四肢软组织肉瘤:初步治疗对疾病控制影响的比较分析。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-26 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1933
Walter S Nardi, Lucía Aragone, Sergio D Quildrian
{"title":"Primary treated versus referred trunk and extremities soft tissue sarcomas: comparative analysis of initial treatment impact on disease control.","authors":"Walter S Nardi, Lucía Aragone, Sergio D Quildrian","doi":"10.3332/ecancer.2025.1933","DOIUrl":"10.3332/ecancer.2025.1933","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Soft tissue sarcomas (STS) are rare and aggressive tumours that require a complex multimodal treatment at referral centers. However, they are often misdiagnosed and subsequently improperly treated at non-specialised centers. A multidisciplinary approach is mandatory for these tumours, involving multiple specialties. Therefore, management should be carried out in reference centers for STS. We aimed to compare oncological outcomes of trunk and extremities STS primarily treated at a reference center versus those referred after initial surgical treatment elsewhere.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;All patients with diagnosis of trunk and extremities STS between January 2010 and May 2024, primarily operated at our center or referred after treatment elsewhere, were included. Visceral, retroperitoneal/pelvic, spermatic cord and head/neck STS were excluded, as well as desmoid tumours and dermatofibrosarcoma protuberans subtype. Demographic data and tumour characteristics were evaluated (location, size, French Federation of Cancer Centers Sarcoma Group grade, neo/adjuvant treatment) as well as primary surgery outcomes (R classification). The cohort was divided into two groups: G1 (primary-resection group) and G2 (referred group). Overall survival (OS), local recurrence-local relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) were compared between groups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 102 trunk and extremities STS underwent surgical resection on the mentioned period, out of which 49 were primarily resected (G1) and 53 had previous resections elsewhere (G2: 33 referred for recurrent tumours and 20 referred after inadequate excision). Data on grade was available for 91 lesions and 67% (61/91) were high-grade, with no significant differences between groups. The two groups had statistically significant differences in median tumour size (G1: 9.5 cm versus G2: 4 cm; &lt;i&gt;p&lt;/i&gt; &lt; 0.001), preoperative radiotherapy (6 versus 0; &lt;i&gt;p&lt;/i&gt; = 0.01) and complete resection margins at first surgery (G1: 46 versus G2 3; &lt;i&gt;p&lt;/i&gt; = 0.0001). All patients in G1 had macroscopic complete bloc resections (94% R0 and 6% planned R1 margins). In G2, residual disease was present in 35% (7/20) of the re-resection specimens. All recurrent tumours had macroscopic complete resections at our center (80% R0 and 20% R1 margins). Discussion within a specialised multidisciplinary tumour board was also significantly different between both groups of patients (98% versus 3.8%; &lt;i&gt;p&lt;/i&gt; &lt; 0.00001). Three-year LRFS was found to be significantly better when primary surgery was performed at a reference center, with 91% versus 32% (log-rank &lt;i&gt;p&lt;/i&gt; &lt; 0.0001). No differences were seen in 3-year DMFS (68.7% versus 72.6%, p = 0.55) and OS (85.3% versus 88.1%, &lt;i&gt;p&lt;/i&gt; = 0.72). Positive resection margins at first surgery correlated with worse LRFS (OR 23.1, &lt;i&gt;p&lt;/i&gt; = 0.01).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Better local control was ach","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1933"},"PeriodicalIF":1.2,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uptake of breast cancer screening methods: perspectives of members of staff of Federal Medical Centre, Abeokuta. 采用乳腺癌筛查方法:阿贝奥库塔联邦医疗中心工作人员的观点。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-24 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1930
Jessica O Esangbedo, Rachael O Oduyemi, Damilare Aduroja, Yetunde O Tola, Olajumoke Dele-Alonge, Emmanuel O Adesuyi, Michael O Ajiboye, Oluwadamilare Akingbade
{"title":"Uptake of breast cancer screening methods: perspectives of members of staff of Federal Medical Centre, Abeokuta.","authors":"Jessica O Esangbedo, Rachael O Oduyemi, Damilare Aduroja, Yetunde O Tola, Olajumoke Dele-Alonge, Emmanuel O Adesuyi, Michael O Ajiboye, Oluwadamilare Akingbade","doi":"10.3332/ecancer.2025.1930","DOIUrl":"10.3332/ecancer.2025.1930","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer (BC) was ranked the most common among the top ten malignancies in 2022, evidenced by high incidence and rates rapid mortality and morbidity rates in Nigeria. BC screening method (BCSM) helps to discover BC early, gives more treatment options and raises cancer survival rates. Little is known about the utilisation of BCSM in this community, which prompted this study.</p><p><strong>Objective: </strong>This study was conducted among the staff of the Federal Medical Center, Abeokuta, and it assessed their knowledge, attitudes and use of BCSM.</p><p><strong>Methods: </strong>This study selected 270 staff members using a descriptive cross-sectional method and a convenience sampling technique. Data were analysed using the Statistical Package for Social Sciences version 25.0. Hypotheses were tested using chi-square, multiple linear regression and Pearson correlation coefficient at a 0.05 level of significance.</p><p><strong>Results: </strong>The study's results showed a high BCSM knowledge level of 71.9% but a low utilisation level of 57.8%; however, there was a positive attitude towards utilisation. Additionally, there was a significant relationship between staff members' gender, age, educational qualifications, department and both their knowledge and utilisation of BCSM (p < 0.05). The Pearson correlation revealed a positive trend between knowledge and utilisation.</p><p><strong>Conclusion: </strong>BCSM offers an opportunity for early detection, diagnosis and disease prevention of BC; it also serves as an avenue to inform and enlighten people on important health issues, including health promotion activities and screening as they pertain to BC. More BC awareness programs are advocated to educate people on the importance of BC Screening to enhance early detection and treatment.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1930"},"PeriodicalIF":1.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changing paradigms in pediatric cancer care - the contemporary landscape and perspectives for India. 在儿科癌症护理的变化范式-当代景观和印度的观点。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-24 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1931
Badira Cheriyalinkal Parambil, Nirmalya Roy Moulik, Venkata Rama Mohan Gollamudi, Shyam Srinivasan, Chetan Dhamne, Akanksha Chichra, Gaurav Narula, Mukta Ramadwar, Sumeet Gujral, Tanuja Shet, Epari Sridhar, Poonam Panjwani, Uma Sakhadeo, Siddhartha Laskar, Nehal Khanna, Jifmi Jose Manjali, Sajid Qureshi, Vasundhara Patil, Akshay Baheti, Sneha Shah, Kunal Gala, Pappagudi Subramanian, Prashant Tembhare, Nikhil Patkar, Gaurav Chatterjee, Sweta Rajpal, Dhanlaxmi Shetty, Maya Prasad, Girish Chinnaswamy
{"title":"Changing paradigms in pediatric cancer care - the contemporary landscape and perspectives for India.","authors":"Badira Cheriyalinkal Parambil, Nirmalya Roy Moulik, Venkata Rama Mohan Gollamudi, Shyam Srinivasan, Chetan Dhamne, Akanksha Chichra, Gaurav Narula, Mukta Ramadwar, Sumeet Gujral, Tanuja Shet, Epari Sridhar, Poonam Panjwani, Uma Sakhadeo, Siddhartha Laskar, Nehal Khanna, Jifmi Jose Manjali, Sajid Qureshi, Vasundhara Patil, Akshay Baheti, Sneha Shah, Kunal Gala, Pappagudi Subramanian, Prashant Tembhare, Nikhil Patkar, Gaurav Chatterjee, Sweta Rajpal, Dhanlaxmi Shetty, Maya Prasad, Girish Chinnaswamy","doi":"10.3332/ecancer.2025.1931","DOIUrl":"10.3332/ecancer.2025.1931","url":null,"abstract":"<p><p>Advances in the diagnosis and management of childhood cancers have significantly improved survival, and 80% of those who have access to contemporary treatment are expected to survive into adulthood. Multimodality protocols incorporating high-intensity cytotoxic chemotherapy and radiotherapy may be associated with increased acute and delayed adverse effects, thereby compromising the quality of life. Furthermore, curative therapeutic options remain limited in the context of metastatic, relapsed or refractory disease as well as rare tumour entities. This has prompted a paradigm shift in pediatric oncology care in the contemporary era, encompassing multiple domains including cancer predisposition, immunotherapy, precision medicine and survivorship, aimed at optimising survival while minimising treatment-related toxicity and improving quality of life. While these advances are increasingly evident in high-income countries, several hurdles and challenges exist in the implementation of these strategies in low-income and middle-income countries (LMICs). Key barriers include restricted accessibility and affordability of newer and advanced diagnostic modalities and therapeutic agents, deficient infrastructure, non-availability of targeted agents and newer immunotherapy drugs, logistical and regulatory hurdles, limited access to clinical trials and inadequate long-term follow-up. Substantial changes are requisite to facilitate the translation of these changing paradigms into reality in India and LMICs.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1931"},"PeriodicalIF":1.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical profile and outcomes of young women with denovo-metastatic breast cancer: real-world data from a tertiary care centre in India. 年轻女性原发性转移性乳腺癌的临床概况和结果:来自印度三级保健中心的真实数据。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-24 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1932
Sushmita Rath, Mehak Trikha, Laboni Sarkar, Kunal Jobanputra, Akash Pawar, Revathy Krishnamurthy, Ayushi Sahay, Ayushi Sahay, Purvi Thakkar, Sneha Shah, Venkatesh Kapu, Anbarasan Sekar, Prabhat Bhargava, Seema Gulia, Rima Pathak, Tabassum Wadasadawala, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta, Jyoti Bajpai
{"title":"Clinical profile and outcomes of young women with denovo-metastatic breast cancer: real-world data from a tertiary care centre in India.","authors":"Sushmita Rath, Mehak Trikha, Laboni Sarkar, Kunal Jobanputra, Akash Pawar, Revathy Krishnamurthy, Ayushi Sahay, Ayushi Sahay, Purvi Thakkar, Sneha Shah, Venkatesh Kapu, Anbarasan Sekar, Prabhat Bhargava, Seema Gulia, Rima Pathak, Tabassum Wadasadawala, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta, Jyoti Bajpai","doi":"10.3332/ecancer.2025.1932","DOIUrl":"10.3332/ecancer.2025.1932","url":null,"abstract":"<p><strong>Background: </strong>Denovo metastatic young breast cancer (dnmYBC), defined as age <40 years, is a challenging entity, with a significant burden and sparse data from low and middle-income countries.</p><p><strong>Method: </strong>We analysed the prospectively collected data of dnmYBC women from 2015 to 2016.</p><p><strong>Results: </strong>There were 188 dnmYBC with a median age of 35.5 years. Of these, hormone receptor positive (HR+) were 72 (38.3) %, triple-negatives (TNBC) were 45 (23.9) %, Human Epidermal Growth Factor Positive (HER2+) were 42 (22.4) % and triple positives were 29 (15.4) %. TNBC women predominantly had visceral 40 (88.9%) metastasis, HR+ had nodal 51 (70.8%) and skeletal 10 (13.8%), while HER2+ women had higher brain metastasis (BM) 16 (38.1%).At a median follow-up of 39.8 [Interquartile range (IQR): 24-55.5] months, the median event-free survival (EFS) was 9.3 (95% CI; 8.1-10.4) months for the entire cohort and 1-year, 2-year and 3-year predicted EFS were 47.8%, 13.4% and 3%, respectively. The median EFS was superior in HR+ women.[15.7 months, hormone receptor (HR)-0.53;95% CI-9.8-21.7; p-0.013] versus (11.4 months, 95 %CI-5.9-16.8) in TNBC versus (7.7 months, 95% CI-6.0-9.5) in HER-2 + women and without BM at baseline [9.3 versus 3.0 months (with BM), HR-5.65; CI-1.72-17.9; <i>p</i>-0.001]. Median EFS was superior in the treatment-naïve (155, 82.4%) versus prior-treated (33, 17.5%) women, 35.5 (95% CI:12.24-58.72) versus 12.4 (95% CI:11.45-13.51) months; <i>p</i>-0.000]. The HER2+ women who received targeted therapy in the first line had a significantly superior median EFS of 13.0 versus 7.7 months (HR -0.465:CI 0.22-0.57: <i>p</i>-0.038).</p><p><strong>Conclusion: </strong>Denovo mYBC is associated with an aggressive course, poor prognosticators include HR negative disease, brain metastasis, inadvertent prior treatment and inadequate access to targeted therapies. Early diagnosis, prompt treatment and expanding accessibility are warranted to improve care.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1932"},"PeriodicalIF":1.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare case of primary invasive urothelial carcinoma of the renal pelvis and calyx: a case report. 原发性肾盂及肾盂浸润性尿路上皮癌1例报告。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-20 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1928
Olatunde Olaniyi Abiodun Oluwafemi, Eberechukwu Uchime Kasiemobi, Mustapha Babatunde, Bankole Kofi Adedeji, Oyelayo Oluwaseun Olaoluwa, Ismaheel Aderogba Azeez, Ezekpo Okechukwu Obumneme
{"title":"A rare case of primary invasive urothelial carcinoma of the renal pelvis and calyx: a case report.","authors":"Olatunde Olaniyi Abiodun Oluwafemi, Eberechukwu Uchime Kasiemobi, Mustapha Babatunde, Bankole Kofi Adedeji, Oyelayo Oluwaseun Olaoluwa, Ismaheel Aderogba Azeez, Ezekpo Okechukwu Obumneme","doi":"10.3332/ecancer.2025.1928","DOIUrl":"10.3332/ecancer.2025.1928","url":null,"abstract":"<p><p>Upper urinary tract urothelial carcinomas (UTUCs) are rare malignant neoplasms, representing about 5% of all urothelial carcinomas (UCs). The incidence of primary UTUC in the renal pelvis and calyx is quite rare. UTUC is a high-grade tumour with a poor prognosis at presentation. Characteristically, UTUC presents with symptoms such as gross and microscopic hematuria or flank pain. Its mode of definitive diagnosis remains histopathology examination, despite using computed tomography urography (CTU) as the gold imaging standard. However, atypical clinical presentations and abnormal radiologic findings could lead to misdiagnosis of UTUC. We report a 59-year-old male who presented with recurrent left flank pain of 2 years duration, and an episode of hematuria. A CTU showed no classic radiologic feature of upper UCs; however, his abdominal magnetic resonance imaging was suggestive. He subsequently had a left radical nephroureterectomy. The post-operative histology report showed a primary invasive high-grade UC of the left renal pelvis and calyx. He was counseled on the findings and placed on surveillance. There are few reported cases of UTUC of the renal pelvis and renal calyx; given that it is a rare malignancy. This is quite concerning, especially with the missed imaging finding by CTU.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1928"},"PeriodicalIF":1.2,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality indicators and patient outcome measures for palliative care in cancer patients: a systematic review. 癌症患者姑息治疗的质量指标和患者结局测量:系统回顾。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-20 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1929
Chase Peng Yun Ng, Moira Hegyi, Grant Lewison, Tania Pastrana, Eve Namisango, James Cleary, Barbara Hasties, Eric Kabisa, Helena Musau, Kathryn Spangenberg, Paola Ruiz, Zipporah Ali, Mertixell Mallafre-Larrosa, Alfredo Polo, Julie Torode, Ajay Aggarwal, Richard Sullivan, Mevhibe Hocaoglu
{"title":"Quality indicators and patient outcome measures for palliative care in cancer patients: a systematic review.","authors":"Chase Peng Yun Ng, Moira Hegyi, Grant Lewison, Tania Pastrana, Eve Namisango, James Cleary, Barbara Hasties, Eric Kabisa, Helena Musau, Kathryn Spangenberg, Paola Ruiz, Zipporah Ali, Mertixell Mallafre-Larrosa, Alfredo Polo, Julie Torode, Ajay Aggarwal, Richard Sullivan, Mevhibe Hocaoglu","doi":"10.3332/ecancer.2025.1929","DOIUrl":"10.3332/ecancer.2025.1929","url":null,"abstract":"<p><strong>Introduction: </strong>With the exponential rise in global cancer incidence, the surge in demand for palliative care has outstripped capacity, limiting patients' access to quality and holistic palliative care, especially in low- and middle-income countries. Despite an upturn in research activity, evidence in palliative care remains limited, given its complexity as well as the shortage of standardised quality indicators (QIs) and patient outcome measures (POMs). The objective of this systematic review is to assess the QIs and POMs used to evaluate palliative care service on aggregated and individual levels.</p><p><strong>Methods: </strong>We undertook a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines to determine the QIs and/or POMs of palliative care in patients with non-communicable diseases. A Web of Science, EMBASE, PubMed and SOCSCI search between 1 January 2013 and 31 Dec 2022 identified 41 articles. We appraised the quality of all studies using the mixed methods appraisal tool.</p><p><strong>Results: </strong>26.8% of studies focus on QIs, while 73.2% used POMs. >90% of palliative care research took place in high-income settings. Across domains of palliative care, the outcome of care is most studied, while the structure and process of palliative care are understudied. QIs and POMs identified often had overlapping themes. Due to the multidimensionality and intricacy of palliative care, evidence is limited, patchy and heterogenous in quality.</p><p><strong>Discussion: </strong>There is an overall lack of standardisation of QIs and POMs, as well as variability in evidence of palliative care research. We recommend that stakeholders collaborate to develop a standardised repository of metrics for monitoring and evaluating palliative care services at both individual and system levels, with a particular focus on structural and process indicators. Incorporating validated, patient-centred measures and selecting key items as quality indicators will enable meaningful tracking of changes, guiding resource allocation and driving improvements in patient-centred care. Furthermore, exploring alternative research designs is essential to enhance feasibility, uphold ethical integrity and strengthen the robustness of future studies.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1929"},"PeriodicalIF":1.2,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mortality rate for mesothelioma as a basic cause in the period 2017-2022 in Chile. 智利2017-2022年期间间皮瘤作为基本病因的死亡率。
IF 1.2
ecancermedicalscience Pub Date : 2025-06-18 eCollection Date: 2025-01-01 DOI: 10.3332/ecancer.2025.1927
Francisca Quintanilla, Álvaro Torres, Monserrat Villar, Catalina Muñoz, José Lizama, Bárbara Mena
{"title":"Mortality rate for mesothelioma as a basic cause in the period 2017-2022 in Chile.","authors":"Francisca Quintanilla, Álvaro Torres, Monserrat Villar, Catalina Muñoz, José Lizama, Bárbara Mena","doi":"10.3332/ecancer.2025.1927","DOIUrl":"10.3332/ecancer.2025.1927","url":null,"abstract":"<p><strong>Introduction: </strong>Mesothelioma is a neoplasm associated with asbestos exposure. Due to the lack of updated national epidemiological data, it was decided to determine the mortality rate (MT) due to mesothelioma during the period 2017-2022 in Chile.</p><p><strong>Materials and methods: </strong>Observational, descriptive and cross-sectional study. A descriptive analysis of mortality rate (TM) due to mesothelioma as a basic cause during the period 2017-2022 in Chile in patients aged 45 years and older was performed, analysing the variables sex, age, national region, anatomical site affected and place of death. Data were obtained from the Department of Health Statistics and Information and the National Institute of Statistics and were analysed using Microsoft Office Excel. No evaluation by an ethics committee was required.</p><p><strong>Results: </strong>We studied 362 deaths, determining a TM for the period of 0.97 deaths per 100,000 inhabitants, where the highest rate was recorded in 2019. There was a predominance in men, with a male excess MT of 2.19, as well as in those over 80 years of age and residents in the region of Arica and Parinacota. In most cases, the tumour location was not determined, but among those identified, the most frequent was of pleural origin. Most deaths occurred at home.</p><p><strong>Discussion: </strong>The findings show that the highest MTs are concentrated in men, the elderly and mining regions, groups in which exposure to asbestos is quite probable, both for occupational and residential reasons.</p><p><strong>Conclusion: </strong>The need to maintain active surveillance and high suspicion for mesothelioma is emphasised, with the application of public health measures for early diagnosis and adequate management.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1927"},"PeriodicalIF":1.2,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信